Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.32 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16447647 | 1.00 | LMNA (0.39) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL299392 | 1.00 | LMNA (0.39) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL16447632 | 0.95 | LMNA (0.36) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL28602862 | 0.95 | LMNA (0.36) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL16447628 | 0.95 | LMNA (0.36) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL2559259 | 0.95 | LMNA (0.36) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL7113425 | 0.86 | LMNA (0.32) | LMNAL3MBTL1TDP1 | |
| SCHEMBL3645857 | 0.81 | LMNA (0.46) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL9344449 | 0.81 | LMNA (0.46) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL7118200 | 0.81 | AKR1B1 (0.30) | AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230255201-A1 | METHODS FOR MANAGING HERBICIDE VAPORIZATION | AGQUAM R&D, LLC | 2023-08-17 | — | — | US | claimed |
| US-20190313640-A1 | METHODS FOR MANAGING HERBICIDE VAPORIZATION | AGQUAM R&D, LLC | 2019-10-17 | — | — | US | claimed |
| EP-3471540-A1 | METHODS FOR MANAGING HERBICIDE VAPORIZATION | Agquam LLC (US) | 2019-04-24 | — | — | EP | claimed |
| US-9854795-B2 | Drift reduction compositions for agricultural use | AgQuam LLC (US) | 2018-01-02 | — | — | US | claimed |
| WO-2017222992-A1 | METHODS FOR MANAGING HERBICIDE VAPORIZATION | AgQuam LLC (US) | 2017-12-28 | — | — | WO | claimed |
| US-20150045224-A1 | Drift Reduction Compositions for Agricultural Use | AgQuam LLC | 2015-02-12 | — | — | US | claimed |
| EP-2044035-A1 | PROCESS FOR THE COVALENT COUPLING OF TWO MOLECULES BY MEANS OF A DIELS-ALDER REACTION WITH INVERSE ELECTRON REQUIREMENT | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts (DE) | 2009-04-08 | — | — | EP | claimed |
| WO-2007144200-A1 | PROCESS FOR THE COVALENT COUPLING OF TWO MOLECULES BY MEANS OF A DIELS-ALDER REACTION WITH INVERSE ELECTRON REQUIREMENT | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2007-12-21 | — | — | WO | claimed |
| EP-1867638-A1 | Procedure for the Conection of two Molecules via Diels-Alder Reactions with Inverse Electron Demand | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2007-12-19 | — | — | EP | claimed |
| WO-2025019943-A1 | SMALL MOLECULE ICE RECRYSTALLIZATION INHIBITORS AND METHODS OF USE THEREOF | UNIVERSITY OF OTTAWA (CA) | 2025-01-30 | — | — | WO | disclosed |
| US-20230255201-A1 | METHODS FOR MANAGING HERBICIDE VAPORIZATION | AGQUAM R&D, LLC | 2023-08-17 | — | — | US | disclosed |
| US-20190313640-A1 | METHODS FOR MANAGING HERBICIDE VAPORIZATION | AGQUAM R&D, LLC | 2019-10-17 | — | — | US | disclosed |
| EP-3471540-A1 | METHODS FOR MANAGING HERBICIDE VAPORIZATION | Agquam LLC (US) | 2019-04-24 | — | — | EP | disclosed |
| US-9854795-B2 | Drift reduction compositions for agricultural use | AgQuam LLC (US) | 2018-01-02 | — | — | US | disclosed |
| EP-2441754-A1 | A new dimedon derivative and a method for the purification of PNA and peptide oligomers | Deutsches Krebsforschungszentrum (DE) | 2012-04-18 | — | — | EP | disclosed |
| US-20100016545-A1 | PROCESS FOR THE COVALENT COUPLING OF TWO MOLECULES BY MEANS OF A DIELS-ALDER REACTION WITH INVERSE ELECTRON REQUIREMENT | DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OFFENTLICHEN RECHTS (DE) | 2010-01-21 | — | — | US | disclosed |
| EP-2044035-A1 | PROCESS FOR THE COVALENT COUPLING OF TWO MOLECULES BY MEANS OF A DIELS-ALDER REACTION WITH INVERSE ELECTRON REQUIREMENT | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts (DE) | 2009-04-08 | — | — | EP | disclosed |
| WO-2007144200-A1 | PROCESS FOR THE COVALENT COUPLING OF TWO MOLECULES BY MEANS OF A DIELS-ALDER REACTION WITH INVERSE ELECTRON REQUIREMENT | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2007-12-21 | — | — | WO | disclosed |
| EP-1867638-A1 | Procedure for the Conection of two Molecules via Diels-Alder Reactions with Inverse Electron Demand | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2007-12-19 | — | — | EP | disclosed |
| WO-2000078844-A1 | MULTIFUNCTIONAL NONIONIC SILOXANE COPOLYMER FOR MODIFICATION OF SYNTHETIC MATERIALS | EURO MANAGEMENT & TRUST COMPANY ESTABLISHMENT (US) | 2000-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016545-A1 | PROCESS FOR THE COVALENT COUPLING OF TWO MOLECULES BY MEANS OF A DIELS-ALDER REACTION WITH INVERSE ELECTRON REQUIREMENT | CX3CR1, NR3C2, NR4A2 | LMNA 4669/4885L3MBTL1 4678/4885TDP1 4603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.